Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

Clinical Significance of Pancreatic Atrophy Induced by Immune-Checkpoint Inhibitors: A Case-Control Study.

Eshet Y, Baruch EN, Shapira-Frommer R, Steinberg-Silman Y, Kuznetsov T, Ben-Betzalel G, Daher S, Gluck I, Asher N, Apter S, Schachter J, Bar J, Boursi B, Markel G.

Cancer Immunol Res. 2018 Dec;6(12):1453-1458. doi: 10.1158/2326-6066.CIR-17-0659. Epub 2018 Oct 1.

PMID:
30275274
2.

Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma.

Ben-Betzalel G, Baruch EN, Boursi B, Steinberg-Silman Y, Asher N, Shapira-Frommer R, Schachter J, Markel G.

Eur J Cancer. 2018 Sep;101:229-235. doi: 10.1016/j.ejca.2018.06.030. Epub 2018 Aug 7.

PMID:
30096703
3.

ADAR1-mediated regulation of melanoma invasion.

Nemlich Y, Baruch EN, Besser MJ, Shoshan E, Bar-Eli M, Anafi L, Barshack I, Schachter J, Ortenberg R, Markel G.

Nat Commun. 2018 May 31;9(1):2154. doi: 10.1038/s41467-018-04600-2.

4.

Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell lung cancer patients.

Ben-Avi R, Farhi R, Ben-Nun A, Gorodner M, Greenberg E, Markel G, Schachter J, Itzhaki O, Besser MJ.

Cancer Immunol Immunother. 2018 Aug;67(8):1221-1230. doi: 10.1007/s00262-018-2174-4. Epub 2018 May 29.

PMID:
29845338
5.

Regulation of CEACAM1 Protein Expression by the Transcription Factor ETS-1 in BRAF-Mutant Human Metastatic Melanoma Cells.

Kfir-Elirachman K, Ortenberg R, Vizel B, Besser MJ, Barshack I, Schachter J, Nemlich Y, Markel G.

Neoplasia. 2018 Apr;20(4):401-409. doi: 10.1016/j.neo.2018.01.012. Epub 2018 Mar 17.

6.

Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors.

Lidar M, Giat E, Garelick D, Horowitz Y, Amital H, Steinberg-Silman Y, Schachter J, Shapira-Frommer R, Markel G.

Autoimmun Rev. 2018 Mar;17(3):284-289. doi: 10.1016/j.autrev.2018.01.003. Epub 2018 Jan 16.

PMID:
29341936
7.

Histopathological expression analysis of intercellular adhesion molecule 1 (ICAM-1) along development and progression of human melanoma.

Galore-Haskel G, Baruch EN, Berg AL, Barshack I, Zilinsky I, Avivi C, Besser MJ, Schachter J, Markel G.

Oncotarget. 2017 Sep 14;8(59):99580-99586. doi: 10.18632/oncotarget.20884. eCollection 2017 Nov 21.

8.

Targeting Multiple Tumors Using T-Cells Engineered to Express a Natural Cytotoxicity Receptor 2-Based Chimeric Receptor.

Eisenberg V, Shamalov K, Meir S, Hoogi S, Sarkar R, Pinker S, Markel G, Porgador A, Cohen CJ.

Front Immunol. 2017 Sep 29;8:1212. doi: 10.3389/fimmu.2017.01212. eCollection 2017.

9.

Selection of Shared and Neoantigen-Reactive T Cells for Adoptive Cell Therapy Based on CD137 Separation.

Seliktar-Ofir S, Merhavi-Shoham E, Itzhaki O, Yunger S, Markel G, Schachter J, Besser MJ.

Front Immunol. 2017 Oct 10;8:1211. doi: 10.3389/fimmu.2017.01211. eCollection 2017.

10.

Perioperative BRAF inhibitors in locally advanced stage III melanoma.

Zippel D, Markel G, Shapira-Frommer R, Ben-Betzalel G, Goitein D, Ben-Ami E, Nissan A, Schachter J, Schneebaum S.

J Surg Oncol. 2017 Dec;116(7):856-861. doi: 10.1002/jso.24744. Epub 2017 Jun 26.

PMID:
28650570
11.

Adoptive T cell therapy: An overview of obstacles and opportunities.

Baruch EN, Berg AL, Besser MJ, Schachter J, Markel G.

Cancer. 2017 Jun 1;123(S11):2154-2162. doi: 10.1002/cncr.30491. Review.

12.

Adoptive Cell Therapy for Metastatic Melanoma.

Merhavi-Shoham E, Itzhaki O, Markel G, Schachter J, Besser MJ.

Cancer J. 2017 Jan/Feb;23(1):48-53. doi: 10.1097/PPO.0000000000000240. Review.

PMID:
28114254
13.

CEACAM1-Mediated Inhibition of Virus Production.

Vitenshtein A, Weisblum Y, Hauka S, Halenius A, Oiknine-Djian E, Tsukerman P, Bauman Y, Bar-On Y, Stern-Ginossar N, Enk J, Ortenberg R, Tai J, Markel G, Blumberg RS, Hengel H, Jonjic S, Wolf DG, Adler H, Kammerer R, Mandelboim O.

Cell Rep. 2016 Jun 14;15(11):2331-9. doi: 10.1016/j.celrep.2016.05.036. Epub 2016 Jun 2.

14.

Adipocytes Viability After Suction-Assisted Lipoplasty: Does the Technique Matter?

Harats M, Millet E, Jaeger M, Orenstein A, Haik J, Hajdu SD, Markel G, Winkler E, Tessone A.

Aesthetic Plast Surg. 2016 Aug;40(4):578-83. doi: 10.1007/s00266-016-0645-6. Epub 2016 May 18.

PMID:
27194429
15.

Metastatic Lung Lesions as a Preferred Resection Site for Immunotherapy With Tumor Infiltrating Lymphocytes.

Ben-Avi R, Itzhaki O, Simansky D, Zippel D, Markel G, Ben Nun A, Schachter J, Besser MJ.

J Immunother. 2016 Jun;39(5):218-22. doi: 10.1097/CJI.0000000000000124.

PMID:
27163742
16.

CEACAM1 and MICA as novel serum biomarkers in patients with acute and recurrent pericarditis.

Markel G, Imazio M, Koren-Morag N, Galore-Haskel G, Schachter J, Besser M, Cumetti D, Maestroni S, Altman A, Shoenfeld Y, Brucato A, Adler Y.

Oncotarget. 2016 Apr 5;7(14):17885-95. doi: 10.18632/oncotarget.7530.

17.

SOX9 indirectly regulates CEACAM1 expression and immune resistance in melanoma cells.

Ashkenazi S, Ortenberg R, Besser M, Schachter J, Markel G.

Oncotarget. 2016 May 24;7(21):30166-77. doi: 10.18632/oncotarget.7379.

18.

Increased serum NKG2D-ligands and downregulation of NKG2D in peripheral blood NK cells of patients with major burns.

Haik J, Nardini G, Goldman N, Galore-Haskel G, Harats M, Zilinsky I, Weissman O, Schachter J, Winkler E, Markel G.

Oncotarget. 2016 Jan 19;7(3):2220-8. doi: 10.18632/oncotarget.6789.

19.

Serum CEACAM1 Elevation Correlates with Melanoma Progression and Failure to Respond to Adoptive Cell Transfer Immunotherapy.

Ortenberg R, Sapoznik S, Zippel D, Shapira-Frommer R, Itzhaki O, Kubi A, Zikich D, Besser MJ, Schachter J, Markel G.

J Immunol Res. 2015;2015:902137. doi: 10.1155/2015/902137. Epub 2015 Nov 25.

20.

A novel immune resistance mechanism of melanoma cells controlled by the ADAR1 enzyme.

Galore-Haskel G, Nemlich Y, Greenberg E, Ashkenazi S, Hakim M, Itzhaki O, Shoshani N, Shapira-Fromer R, Ben-Ami E, Ofek E, Anafi L, Besser MJ, Schachter J, Markel G.

Oncotarget. 2015 Oct 6;6(30):28999-9015. doi: 10.18632/oncotarget.4905.

21.

miR-17 regulates melanoma cell motility by inhibiting the translation of ETV1.

Cohen R, Greenberg E, Nemlich Y, Schachter J, Markel G.

Oncotarget. 2015 Aug 7;6(22):19006-16.

22.

Correction: harnessing soluble NK cell killer receptors for the generation of novel cancer immune therapy.

Arnon TI, Markel G, Bar-Ilan A, Hanna J, Fima E, Benchetrit F, Galili R, Cerwenka A, Benharroch D, Sion-Vardy N, Porgador A, Mandelboim O.

PLoS One. 2015 May 4;10(5):e0128052. doi: 10.1371/journal.pone.0128052. eCollection 2015. No abstract available.

23.

Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis.

Shoshan E, Mobley AK, Braeuer RR, Kamiya T, Huang L, Vasquez ME, Salameh A, Lee HJ, Kim SJ, Ivan C, Velazquez-Torres G, Nip KM, Zhu K, Brooks D, Jones SJ, Birol I, Mosqueda M, Wen YY, Eterovic AK, Sood AK, Hwu P, Gershenwald JE, Robertson AG, Calin GA, Markel G, Fidler IJ, Bar-Eli M.

Nat Cell Biol. 2015 Mar;17(3):311-21. doi: 10.1038/ncb3110. Epub 2015 Feb 16.

24.

Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor TIGIT protects tumors from immune cell attack.

Gur C, Ibrahim Y, Isaacson B, Yamin R, Abed J, Gamliel M, Enk J, Bar-On Y, Stanietsky-Kaynan N, Coppenhagen-Glazer S, Shussman N, Almogy G, Cuapio A, Hofer E, Mevorach D, Tabib A, Ortenberg R, Markel G, Miklić K, Jonjic S, Brennan CA, Garrett WS, Bachrach G, Mandelboim O.

Immunity. 2015 Feb 17;42(2):344-355. doi: 10.1016/j.immuni.2015.01.010. Epub 2015 Feb 10.

25.

A longitudinal study of CEACAM1 expression in melanoma disease progression.

Zippel D, Barlev H, Ortenberg R, Barshack I, Schachter J, Markel G.

Oncol Rep. 2015 Mar;33(3):1314-8. doi: 10.3892/or.2014.3703. Epub 2014 Dec 30.

PMID:
25573088
26.

A mathematical algorithm for detection of late-onset sepsis in very-low birth weight infants: a preliminary diagnostic test evaluation.

Gur I, Markel G, Nave Y, Vainshtein I, Eisenkraft A, Riskin A.

Indian Pediatr. 2014 Aug;51(8):647-50.

27.

Highlights from the latest articles in pharmacogenomics research.

Markel G, Galore-Haskel G, Sullivan R.

Pharmacogenomics. 2014 Jun;15(8):1063-4. doi: 10.2217/pgs.14.55. No abstract available.

PMID:
25084199
28.

Pilot study of a new mathematical algorithm for early detection of late-onset sepsis in very low-birth-weight infants.

Gur I, Riskin A, Markel G, Bader D, Nave Y, Barzilay B, Eyal FG, Eisenkraft A.

Am J Perinatol. 2015 Mar;32(4):321-30. doi: 10.1055/s-0034-1384645. Epub 2014 Jul 31.

PMID:
25077471
29.

CEACAM1 promotes melanoma cell growth through Sox-2.

Ortenberg R, Galore-Haskel G, Greenberg I, Zamlin B, Sapoznik S, Greenberg E, Barshack I, Avivi C, Feiler Y, Zan-Bar I, Besser MJ, Azizi E, Eitan F, Schachter J, Markel G.

Neoplasia. 2014 May;16(5):451-60. doi: 10.1016/j.neo.2014.05.003. Epub 2014 Jun 13.

30.

Differential regulation of aggressive features in melanoma cells by members of the miR-17-92 complex.

Greenberg E, Hajdu S, Nemlich Y, Cohen R, Itzhaki O, Jacob-Hirsch J, Besser MJ, Schachter J, Markel G.

Open Biol. 2014 Jun;4(6):140030. doi: 10.1098/rsob.140030.

31.

Primary malignancies of the heart and pericardium.

Burazor I, Aviel-Ronen S, Imazio M, Markel G, Grossman Y, Yosepovich A, Adler Y.

Clin Cardiol. 2014 Sep;37(9):582-8. doi: 10.1002/clc.22295. Epub 2014 Jun 4. Review.

32.

MicroRNAs in cancer: lessons from melanoma.

Greenberg E, Nemlich Y, Markel G.

Curr Pharm Des. 2014;20(33):5246-59. Review.

PMID:
24479804
33.

A comparative analysis of total serum miRNA profiles identifies novel signature that is highly indicative of metastatic melanoma: a pilot study.

Greenberg E, Besser MJ, Ben-Ami E, Shapira-Frommer R, Itzhaki O, Zikich D, Levy D, Kubi A, Eyal E, Onn A, Cohen Y, Barshack I, Schachter J, Markel G.

Biomarkers. 2013 Sep;18(6):502-8. doi: 10.3109/1354750X.2013.816777. Epub 2013 Jul 29.

PMID:
23902289
34.

MicroRNA-mediated loss of ADAR1 in metastatic melanoma promotes tumor growth.

Nemlich Y, Greenberg E, Ortenberg R, Besser MJ, Barshack I, Jacob-Hirsch J, Jacoby E, Eyal E, Rivkin L, Prieto VG, Chakravarti N, Duncan LM, Kallenberg DM, Galun E, Bennett DC, Amariglio N, Bar-Eli M, Schachter J, Rechavi G, Markel G.

J Clin Invest. 2013 Jun;123(6):2703-18.

35.

Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies.

Besser MJ, Shapira-Frommer R, Itzhaki O, Treves AJ, Zippel DB, Levy D, Kubi A, Shoshani N, Zikich D, Ohayon Y, Ohayon D, Shalmon B, Markel G, Yerushalmi R, Apter S, Ben-Nun A, Ben-Ami E, Shimoni A, Nagler A, Schachter J.

Clin Cancer Res. 2013 Sep 1;19(17):4792-800. doi: 10.1158/1078-0432.CCR-13-0380. Epub 2013 May 20.

36.

Malignant pericardial effusion.

Burazor I, Imazio M, Markel G, Adler Y.

Cardiology. 2013;124(4):224-32. doi: 10.1159/000348559. Epub 2013 Apr 5. Review.

PMID:
23571453
37.

Insulin-like growth factor-binding protein-7 (IGFBP7) transcript: A-to-I editing events in normal and cancerous human keratinocytes.

Hochberg M, Gilead L, Markel G, Nemlich Y, Feiler Y, Enk CD, Denichenko P, Karni R, Ingber A.

Arch Dermatol Res. 2013 Aug;305(6):519-28. doi: 10.1007/s00403-013-1338-5. Epub 2013 Mar 30.

PMID:
23543219
38.

Development of allogeneic NK cell adoptive transfer therapy in metastatic melanoma patients: in vitro preclinical optimization studies.

Besser MJ, Shoham T, Harari-Steinberg O, Zabari N, Ortenberg R, Yakirevitch A, Nagler A, Loewenthal R, Schachter J, Markel G.

PLoS One. 2013;8(3):e57922. doi: 10.1371/journal.pone.0057922. Epub 2013 Mar 4.

39.

Nicotinamide inhibits vasculogenic mimicry, an alternative vascularization pathway observed in highly aggressive melanoma.

Itzhaki O, Greenberg E, Shalmon B, Kubi A, Treves AJ, Shapira-Frommer R, Avivi C, Ortenberg R, Ben-Ami E, Schachter J, Besser MJ, Markel G.

PLoS One. 2013;8(2):e57160. doi: 10.1371/journal.pone.0057160. Epub 2013 Feb 25.

40.

Prevention of recurrent pericarditis with colchicine in 2012.

Markel G, Imazio M, Brucato A, Adler Y.

Clin Cardiol. 2013 Mar;36(3):125-8. doi: 10.1002/clc.22098. Epub 2013 Feb 12. Review.

41.

Adoptive T-cell transfer in melanoma.

Itzhaki O, Levy D, Zikich D, Treves AJ, Markel G, Schachter J, Besser MJ.

Immunotherapy. 2013 Jan;5(1):79-90. doi: 10.2217/imt.12.143. Review.

PMID:
23256800
42.

Adoptive cell therapy with autologous tumor-infiltrating lymphocytes and high-dose interleukin-2 for metastatic melanoma: The surgeon's perspective.

Zippel DB, Besser M, Shapira R, Ben-Nun A, Goitein D, Davidson T, Treves AJ, Markel G, Schachter J, Papa MZ.

Exp Ther Med. 2012 May;3(5):898-902. Epub 2012 Feb 28.

43.

Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms.

Sapoznik S, Hammer O, Ortenberg R, Besser MJ, Ben-Moshe T, Schachter J, Markel G.

Clin Dev Immunol. 2012;2012:818214. doi: 10.1155/2012/818214. Epub 2012 Apr 23. Review.

44.

Novel immunotherapy for malignant melanoma with a monoclonal antibody that blocks CEACAM1 homophilic interactions.

Ortenberg R, Sapir Y, Raz L, Hershkovitz L, Ben Arav A, Sapoznik S, Barshack I, Avivi C, Berkun Y, Besser MJ, Ben-Moshe T, Schachter J, Markel G.

Mol Cancer Ther. 2012 Jun;11(6):1300-10. doi: 10.1158/1535-7163.MCT-11-0526. Epub 2012 Mar 30.

45.

CXCR1 as a novel target for directing reactive T cells toward melanoma: implications for adoptive cell transfer immunotherapy.

Sapoznik S, Ortenberg R, Galore-Haskel G, Kozlovski S, Levy D, Avivi C, Barshack I, Cohen CJ, Besser MJ, Schachter J, Markel G.

Cancer Immunol Immunother. 2012 Oct;61(10):1833-47. Epub 2012 Mar 24.

PMID:
22441657
46.

CEACAM1 in malignant melanoma: a diagnostic and therapeutic target.

Sapoznik S, Ortenberg R, Schachter J, Markel G.

Curr Top Med Chem. 2012;12(1):3-10. Review.

PMID:
22196267
47.

Mutagen-specific mutation signature determines global microRNA binding.

Greenberg E, Rechavi G, Amariglio N, Solomon O, Schachter J, Markel G, Eyal E.

PLoS One. 2011;6(11):e27400. doi: 10.1371/journal.pone.0027400. Epub 2011 Nov 9.

48.

Carcinoembryonic antigen cell adhesion molecule-1 (CEACAM1) in posterior uveal melanoma: correlation with clinical and histological survival markers.

Khatib N, Pe'er J, Ortenberg R, Schachter J, Frenkel S, Markel G, Amer R.

Invest Ophthalmol Vis Sci. 2011 Dec 9;52(13):9368-72. doi: 10.1167/iovs.10-6006.

PMID:
22039239
49.

Meta-analysis of randomized trials focusing on prevention of the postpericardiotomy syndrome.

Imazio M, Brucato A, Markel G, Cemin R, Trinchero R, Spodick DH, Adler Y.

Am J Cardiol. 2011 Aug 15;108(4):575-9. doi: 10.1016/j.amjcard.2011.03.087. Epub 2011 May 31. Review.

PMID:
21624554
50.

Regulation of cancer aggressive features in melanoma cells by microRNAs.

Greenberg E, Hershkovitz L, Itzhaki O, Hajdu S, Nemlich Y, Ortenberg R, Gefen N, Edry L, Modai S, Keisari Y, Besser MJ, Schachter J, Shomron N, Markel G.

PLoS One. 2011 Apr 25;6(4):e18936. doi: 10.1371/journal.pone.0018936.

Supplemental Content

Loading ...
Support Center